Back to Search Start Over

The EC90 of remifentanil for blunting cardiovascular responses to head fixation for neurosurgery under total intravenous anesthesia with propofol and remifentanil based on bispectral index monitoring: estimation with the biased coin up-anddown sequential method.

Authors :
Jung-Man Lee
Jae-Hyon Bahk
Young-Jin Lim
Jiwon Lee
Leerang Lim
Source :
BMC Anesthesiology; 10/10/2017, Vol. 17, p1-7, 7p
Publication Year :
2017

Abstract

Background: Head fixation can induce hemodynamic instability. Remifentanil is commonly used with propofol for total intravenous anesthesia (TIVA) during neurosurgery. This study investigated the 90% effective concentration (EC<subscript>90</subscript>) of remifentanil for blunting of cardiovascular responses to head fixation during neurosurgery via bispectral index (BIS) monitoring. Methods: Fifty patients undergoing neurosurgery requiring head fixation were enrolled. This study was performed using the biased coin up-and-down design sequential method (BCD). After tracheal intubation, the effect-site target concentration (Ce) of remifentanil was adjusted to achieve hemodynamic stability and reset to the level preoperatively assigned to each patient, according to the BCD method, approximately 10 min before head fixation. Baseline hemodynamic values were recorded before head fixation. An ineffective response was defined as a case with a > 20% increase in hemodynamic values from baseline. Otherwise, the response was determined to be effective. The EC<subscript>90</subscript> of remifentanil was calculated as a modified isotonic estimator. Results: Forty-three patients completed this study. The EC<subscript>90</subscript> of remifentanil for blunting cardiovascular responses to head fixation was estimated to be 6.48 ng/mL (95% CI, 5.94-6.83 ng/mL). Conclusions: Adjustment of the Ce of remifentanil to approximately 6.5 ng/mL before head fixation could prevent noxious cardiovascular responses in 90% of neurosurgical ASA I-II patients aged 20 to 65 years old during propofol target-controlled infusion titrated to maintain BIS between 40 and 50. Trial registration: ClinicalTrials.gov Identifier NCT01489137, retrospectively registered 5 December 2011. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14712253
Volume :
17
Database :
Complementary Index
Journal :
BMC Anesthesiology
Publication Type :
Academic Journal
Accession number :
125590436
Full Text :
https://doi.org/10.1186/s12871-017-0426-z